Zenas BioPharma (ZBIO) Cash & Equivalents (2023 - 2026)

Zenas BioPharma's Cash & Equivalents history runs 4 years deep, the most recent figure standing at $500.2 million for Q1 2026.

• On a quarterly basis, Cash & Equivalents rose 59.21% year-over-year to $500.2 million in Q1 2026; TTM through Mar 2026 was $500.2 million, a 59.21% increase from a year earlier, with the FY2025 full-year figure at $110.6 million, down 65.4% from the prior year.
• Cash & Equivalents grew to $500.2 million in Q1 2026 per ZBIO's latest filing, from $110.6 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $500.2 million in Q1 2026 and bottomed at $37.2 million in Q1 2024.
• The 4-year median for Cash & Equivalents is $183.9 million (2024), against an average of $209.2 million.
• Biggest YoY gain for Cash & Equivalents was 745.67% in 2025; the steepest drop was 76.07% in 2025.
• Year by year, Cash & Equivalents stood at $56.9 million in 2023, then jumped by 462.36% to $319.7 million in 2024, then tumbled by 65.4% to $110.6 million in 2025, then surged by 352.11% to $500.2 million in 2026.
• Per Business Quant, the three latest ZBIO Cash & Equivalents figures stand at $500.2 million (Q1 2026), $110.6 million (Q4 2025), and $301.6 million (Q3 2025).